Results 11 to 20 of about 62,270 (271)

Can HRCT be used as a marker of airway remodelling in children with difficult asthma? [PDF]

, 2006
BACKGROUND: Whole airway wall thickening on high resolution computed tomography (HRCT) is reported to parallel thickening of the bronchial epithelial reticular basement membrane (RBM) in adult asthmatics. A similar relationship in children with difficult
A Barbato, A Chetta, AL James, C Owens, C Ward, D Payne, DG Altman, DN Payne, HR Roberts, HW Chu, J de Blic, K Kasahara, KO McKay, P Jeffery, P Sullivan, PA de Jong, PG Woodruff, PK Jeffery, S Saglani, SA Little, SM Stick, TR Bai, V Marchac, Y Nakano   +23 more
core   +3 more sources

Smoking in asthma is associated with elevated levels of corticosteroid resistant sputum cytokines—an exploratory study [PDF]

, 2013
<p>Background: Current cigarette smoking is associated with reduced acute responses to corticosteroids and worse clinical outcomes in stable chronic asthma. The mechanism by which current smoking promotes this altered behavior is currently unclear.
A McKay, A Sykes, B Pedersen, Carl de Wet, Charles McSharry, Christopher J. Weir, E Goleva, E Goleva, E Irusen, E Juniper, E Livingston, GJ Zijlstra, GW Chalmers, GW Chalmers, H Kerstjens, J Kam, J St-Laurent, JEM Tomlinson, M Althuis, M Broekema, M Spears, Marco Idzko, Mark Spears, MR Edwards, MR Miller, MR Stämpfli, NC Thomson, Neil C. Thomson, R Chaudhuri, R Chaudhuri, R Crapo, R Meijer, R Sher, Rekha Chaudhuri, S Holgate, SC Lazarus, SE Pedersen, SE Wenzel, WE Naugler, Z Qiu, Z Xing   +40 more
core   +9 more sources

The blue one takes a battering why do young adults with asthma overuse bronchodilator inhalers? A qualitative study [PDF]

, 2013
Objective: Overuse of short-acting bronchodilators is internationally recognised as a marker of poor asthma control, high healthcare use and increased risk of asthma death. Young adults with asthma commonly overuse short-acting bronchodilators. We sought
Cole, S, Griffiths, C, Seale, C
core   +2 more sources

Pharmacological Modulation of Endotoxin-Induced Release of IL-26 in Human Primary Lung Fibroblasts

Frontiers in Pharmacology, 2019
Background: Interleukin (IL)-26 is a neutrophil-mobilizing and bactericidal cytokine that is enhanced in human airways in vivo in response to endotoxin from Gram-negative bacteria.
Karlhans Fru Che, Jitong Sun, Jitong Sun, Anders Linden, Anders Linden   +4 more
doaj   +1 more source

Longitudinal FEV1 and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling

International Journal of COPD, 2021
Kirill Zhudenkov,1 Robert Palmér,2 Alexandra Jauhiainen,3 Gabriel Helmlinger,4,5 Oleg Stepanov,1 Kirill Peskov,1,6 Ulf G Eriksson,2 Ulrika Wählby Hamrén2 1M&S Decisions LLC, Moscow, Russia; 2Clinical Pharmacology & Quantitative
Zhudenkov K, Palmér R, Jauhiainen A, Helmlinger G, Stepanov O, Peskov K, Eriksson UG, Wählby Hamrén U   +7 more
doaj  

The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD : current evidence and future prospects [PDF]

, 2019
Long-acting bronchodilators are the cornerstone of pharmacologic treatment of chronic obstructive pulmonary disease (COPD). Spiolto (R) or Stiolto (R) is a fixed-dose combination (FDC) containing two long-acting bronchodilators, the long-acting ...
Brusselle, Guy, Derom, Eric, Joos, Guy
core   +1 more source

Pharmacological Validation for the Folklore Use of Ipomoea nil against Asthma: In Vivo and In Vitro Evaluation

Molecules, 2022
Oxidative stress is the key factor that strengthens free radical generation which stimulates lung inflammation. The aim was to explore antioxidant, bronchodilatory along with anti-asthmatic potential of folkloric plants and the aqueous methanolic crude ...
Taha Alqahtani, Sajida Parveen, Yahia Alghazwani, Hanan M. Alharbi, Reem M. Gahtani, Nadia Hussain, Kashif ur Rehman, Musaddique Hussain   +7 more
doaj   +1 more source

Triple Therapy of Fluticasone Furoate, Umeclidinium, Vilanterol- A Compelling Choice in Severe Chronic Obstructive Pulmonary Disease [PDF]

Journal of Clinical and Diagnostic Research, 2021
Trelegy Ellipta (GlaxoSmithKlineTM) is the first single inhaler triple combination therapy comprising of umeclidinium, vilanterol and fluticasone approved by the United States Food and Drug Administration (US FDA) for patients with severe COPD in 2019.
B Jagan Nathan, Melina I Sahay, AK Gautham, DK Sriram, Melvin George   +4 more
doaj   +1 more source

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: A randomized non-inferiority study [PDF]

, 2018
Background: Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg has been shown to improve lung function and health status, and reduce exacerbations, versus budesonide/formoterol in patients with chronic obstructive ...
Birk, Ruby, Brealey, Noushin, Bremner, Peter R, Ismaila, Afisi S, Lipson, David A, Zhu, Chang-Qing   +5 more
core   +2 more sources

Impulse oscillometry identifies peripheral airway dysfunction in children with adenosine deaminase deficiency. [PDF]

, 2015
Adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) is characterized by impaired T-, B- and NK-cell function. Affected children, in addition to early onset of infections, manifest non-immunologic symptoms including pulmonary ...
Candotti, Fabio, Hershfield, Michael S, Kohn, Donald B, Komarow, Hirsh D, Metcalfe, Dean D, Sokolic, Robert, Young, Michael   +6 more
core   +2 more sources